UPB supply chain intelligence for Upstream Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Upstream Bio, Inc. (UPB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 92% | On March 26, 2026, Upstream Bio, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (the “Agent”), pursuant to which the Company fro… |
| ASTELLAS-PHARMA-INC | ASTELLAS-PHARMA-INC | 90% | Pursuant to the Astellas Asset Purchase Agreement, we purchased from Astellas the compound designated by Astellas as ASP7266 |
| REGN | Regeneron Pharmaceuticals, Inc. | 80% | Reciprocal relationship from REGN graph: Reciprocal relationship from UPB graph: The Regeneron Letter Agreement relates to a prior Non-Exclusive License and Material Transfer Agreement that Regeneron… |
| REGN | Regeneron Pharmaceuticals, Inc. | 80% | The Regeneron Letter Agreement relates to a prior Non-Exclusive License and Material Transfer Agreement that Regeneron and Astellas entered into |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from UPB graph: ise such that they may be more successful than us in obtaining regulatory approval and achieving widespread market acce… |
| AZN | AstraZeneca PLC | 72% | ise such that they may be more successful than us in obtaining regulatory approval and achieving widespread market acceptance. • We expect to expand our organization, and as a result, we may encounte… |
| SNYNF | Sanofi | 72% | or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued dra… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforceme… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MARUHO | MARUHO | 90% | The Company concluded that Maruho is a customer under the Maruho Agreement, and as such, the Maruho Agreement falls within the scope of ASC 606 |
| MYGN | Myriad Genetics, Inc. | 72% | liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In addition, we may incur substantial cost… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from UPB graph: liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biologica… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | llaboration arrangements with third parties. Until we can generate sufficient product revenue to finance our cash requirements, if ever, we expect to fund our operations through equity offerings or d… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from UPB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from UPB graph: Reciprocal relationship from REGN gra… |
| SNYNF | Sanofi | 72% | or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued dra… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: or development of AI technologies. … |
| ASTELLAS-PHARMA-INC | ASTELLAS-PHARMA-INC | 62% | ntinue to incur significant financial losses for the foreseeable future. We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in April 2021 and our opera… |
| KONG-LIMITED | KONG-LIMITED | 62% | g Kong) Limited to manufacture the Compound, requiring us to pay a mid-six-figure annual fee to Lonza pursuant to this provision. Any royalties due under the Lonza License Agreement are payable on a … |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | rch 31, 2025. The increase of $1.3 million was primarily driven by an increase in personnel expenses of $0.7 million due to increased headcount in our general and administrative functions. Personnel … |
| LONZA-SALES-AG | LONZA-SALES-AG | 62% | llaboration arrangements with third parties. Until we can generate sufficient product revenue to finance our cash requirements, if ever, we expect to fund our operations through equity offerings or d… |
| MARUHO-CO-LTD | MARUHO-CO-LTD | 62% | e continue to make investments to improve the protection of data and information technology, including in the hiring of information technology (“IT”) personnel, periodic cyber security awareness trai… |
| PLAB | Photronics, Inc. | 62% | Reciprocal relationship from PLAB graph: Reciprocal relationship from UPB graph: Reciprocal relationship from PLAB graph: Reciprocal relationship from UPB graph: Reciprocal relationship from PLAB gra… |
| REGENERON-PHARMACEUTICALS-INC | REGENERON-PHARMACEUTICALS-INC | 62% | ntinue to incur significant financial losses for the foreseeable future. We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in April 2021 and our opera… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| UPB-DEBT | Debt stack $1.1M | 90% | Market cache reports total debt of $1.1M. |
| UPB-DEBT-13229 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| UPB-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 144 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['supplier'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 |